Abstract #1118
Non-Invasive Imaging Biomarkers of Tumor Response to XL184 Therapy
Benjamin A Hoff 1 , Jean-Christophe Brisset 2 , Stefanie Galbn 3 , Craig J Galbn 1 , and Brian D Ross 1
1
Radiology, University of Michigan, Ann
Arbor, MI, United States,
2
New
York University Langone, NY, United States,
3
Radiation
Oncology, University of Michigan, MI, United States
Clinical response criteria (RECIST 1.1) considers boney
metastases measuring >10mm without soft tissue
involvement as unmeasurable. The clinical need for
accurate therapeutic response measures is more pressing
with the introduction of targeted therapies into
standard of treatment. XL184 is a novel tyrosine kinase
inhibitor that exhibits activity against mainly MET and
VEGFR-2.1 We evaluated DW-MRI and CT pre- and
post-therapy on a mouse model of bone-metastatic
prostate cancer to assess early treatment response to
this therapy. The therapeutic effect of XL184 was
observed via several readouts, with mean tumor ADC
increasing significantly over controls by day 3
post-therapy.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
